The clinical innovation stems from the Phase 1 inMMyCAR study, which introduces KLN-1010, an experimental therapeutic agent developed by Kelonia Therapeutics. Diverging from traditional CAR-T cell protocols that necessitate the extraction and external engineering of T cells followed by re-infusion into patients, KLN-1010 employs an in vivo approach. This strategy generates chimeric antigen receptor T cells directly inside the patient’s body, thereby streamlining the therapeutic process, mitigating delays commonly associated with cell manufacturing, and obviating the need for lymphodepleting chemotherapy regimens that often precede CAR-T cell administration.

The in vivo gene placement system (iGPS) platform developed by Kelonia serves as the technological foundation underpinning KLN-1010. By leveraging advanced lentiviral vector delivery systems equipped with envelope modifications and tropism molecules, the platform achieves highly efficient and targeted transduction of T cells in situ. This platform-enhanced specificity fosters robust anti-tumor activity while minimizing off-target effects, thereby potentiating both the safety and effectiveness profiles of the therapy.

Winship Cancer Institute’s rapid activation as the second U.S. site in the global inMMyCAR trial and their distinction as the first institution to administer KLN-1010 on American soil highlight the institute’s leadership in accelerating access to cutting-edge clinical trials. This expedited trial deployment was facilitated through a concerted effort among multidisciplinary teams encompassing myeloma specialists, clinical operations, and research coordinators, emphasizing collaboration as key to cutting bureaucratic delays often hindering trial activation.

Multiple myeloma, a malignancy arising from plasma cells residing in bone marrow, remains challenging to treat despite recent therapeutic progress. Patients with relapsed or refractory forms face limited options and underscore an urgent need for novel therapies that can overcome resistance mechanisms. Traditional CAR-T treatments, although groundbreaking, are hampered by complex logistical challenges and toxicities related to preparative chemotherapy, factors that in vivo CAR-T therapies like KLN-1010 aim to resolve.

Preliminary data presented at the recent American Society of Hematology annual meeting provide a cautiously optimistic outlook, demonstrating encouraging early clinical responses and tolerability in the initial cohort of treated patients. While these findings kindle hope for improved outcomes, investigators underscore the investigational nature of the therapy, necessitating further longitudinal studies to ascertain durability of response and long-term safety implications.

Leading hematology experts at Winship have highlighted the transformative potential of this modality. The in vivo generative paradigm offers prospects for markedly reducing the time to treatment initiation and expanding patient accessibility, particularly for those who might otherwise be ineligible for cell collection or cannot tolerate traditional conditioning regimens. Such advancements could ultimately democratize CAR-T therapy, elevating it from a complex, resource-intensive intervention to a more routine and widely deployable treatment.

Kelonia Therapeutics continues to advance its pipeline using the iGPS platform to develop gene therapies across multiple indications, driven by the ambition to make CAR-T cell therapies accessible when and where patients need them. The successful deployment of KLN-1010 in this trial also sets a precedent for employing in vivo gene therapies in hematologic malignancies, propelling the field towards more patient-friendly, efficient, and scalable immunotherapeutic solutions.

The significance of Winship Cancer Institute’s role as Georgia’s sole National Cancer Institute-designated Comprehensive Cancer Center extends beyond delivering therapies. It provides a vital infrastructure to integrate breakthrough scientific discoveries into clinical care rapidly, fosters robust translational research, and cultivates an ecosystem where patients gain access to promising experimental treatments that might redefine standard-of-care paradigms.

In summary, the initiation of in vivo CAR-T therapy administration in the United States represents a pivotal inflection point in multiple myeloma treatment. It encapsulates the convergence of innovative gene delivery technologies, clinical expertise, and coordinated research efforts aimed at overcoming existing therapeutic barriers. Success in ongoing trials could herald a new era in oncology, wherein gene-modified immune cells are generated seamlessly within patients, offering safer, faster, and more accessible cancer immunotherapies.

Subject of Research: Investigational in vivo CAR-T cell therapy for relapsed and refractory multiple myeloma
Article Title: Winship Cancer Institute Administers First In Vivo CAR-T Therapy in U.S. for Multiple Myeloma
News Publication Date: May 13, 2026
Web References: https://www.keloniatx.com/
Keywords: in vivo CAR-T therapy, multiple myeloma, KLN-1010, chimeric antigen receptor T cells, Kelonia Therapeutics, in vivo gene placement system, phase 1 clinical trial, cancer immunotherapy, investigational therapy, lentiviral vector, hematologic malignancies, Winship Cancer Institute